ERBB2 overexpression is a mechanism of acquired resistance for NSCLC patients without the EGFR T790M mutation after EGFR-TKI treatment, potentially initiated by ERBB3 which strongly activates downstream PI3K/Akt signaling [31,32,33,34,35]. Here, ERBB2 is linked to non-small cell lung carcinoma.